Add non-alcoholic fatty liver disease (NAFLD) to the list of conditions that cannabis can help curb.
A new study published in the journal PLoS One found that cannabis-friendly adults are less likely to develop the most prevalent form of liver disease – affecting 80 to 100 million Americans – than those without a history of cannabis use.
Researchers from California’s Stanford University and South Korea’s Seoul National University College of Medicine looked at the relationship between cannabis and NAFLD in a nationally representative sample of more than 22,000 adults.
They found that cannabis use independently predicted a lower risk of suspected NAFLD in a dose-dependent manner.
“Active marijuana use provided a protective effect against NAFLD independent of known metabolic risk factors,” reads the study.
“[W]e conclude that current marijuana use may favorably impact the pathogenesis of NAFLD in US adults.”
These results reflect a study previously published in the same journal, which found that heavy cannabis consumers were 52 percent less likely – and occasional consumers 15 percent less likely – than non-users to suffer from NAFLD.
Another study published earlier this month in the Journal of Viral Hepatitis found that routine cannabis use is linked with a reduced prevalence of fatty liver disease in those with HIV and hepatitis C.
h/t NORML blog